CRT Capital Thursday morning ratings report included a coverage initiation by analyst Arlinda Lee on Oncogenex Pharmaceuticals (NASDAQ: OGXI) with a Buy rating and price target of $20. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) rose 8.88 percent to $13.85 yesterday on volume of 483,342million shares. The intra-day range of the stock was $12.61 to $13.95. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) has a market capitalization of $203.70million.

Emergent Biosolutions Inc (NYSE:EBS) was downgraded byZacks from an “outperform” rating to a “neutral” rating in a research note issued on Monday. Emergent Biosolutions Inc (NYSE:EBS)’s stock on Mar 10, 2014 reported a increase of 1.15% to the closing price of $28.09. Its fifty two weeks range is $13.02 -$28.48. The total market capitalization recorded $1.02billion. The overall volume in the last trading session was 379,942.00million shares. In its share capital, EBS has 36.27million outstanding shares.

German health regulators have granted Northwest Biotherapeutics Inc (NASDAQ:NWBO) special permission to sell its experimental brain cancer drug, DCVax-L. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) stock performance was 29.55% in last session and finished the day at $7.85. Traded volume was 6.18million shares in the last session and the average volume of the stock remained 913.66K shares. The beta of the stock remained 2.82. Northwest Biotherapeutics, Inc (NASDAQ:NWBO) insider ownership is 9.86%.

Xencor, Inc. (NASDAQ:XNCR) is a clinical-stage biopharmaceutical company. The Company focused on discovering and developing engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. On Monday, shares of Xencor Inc (NASDAQ:XNCR) advanced 4.40% to close the day at $13.05. Company return on investment (ROI) is 4.30% and its monthly performance is recorded as 42.31%.